BTIG analyst Sam Eiber upgraded Apyx Medical (APYX) to Buy from Neutral with a $6 price target The firm cites positive early momentum with the Ayon launch, growing demand for skin tightening among consumers taking GLP-1s, and Apyx Medical’s expansion opportunities outside the U.S. for the upgrade. Accelerating growth and cost controls offer greater visibility into the company’s path to sustainable profitability, which had been a previous core concern, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APYX: